<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">20706656</PMID>
      <DateCompleted>
        <Year>2010</Year>
        <Month>11</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1466-1861</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2010</Volume>
            <PubDate>
              <Year>2010</Year>
            </PubDate>
          </JournalIssue>
          <Title>Mediators of inflammation</Title>
          <ISOAbbreviation>Mediators Inflamm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>DAMPening inflammation by modulating TLR signalling.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">672395</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2010/672395</ELocationID>
        <Abstract>
          <AbstractText>Damage-associated molecular patterns (DAMPs) include endogenous intracellular molecules released by activated or necrotic cells and extracellular matrix (ECM) molecules that are upregulated upon injury or degraded following tissue damage. DAMPs are vital danger signals that alert our immune system to tissue damage upon both infectious and sterile insult. DAMP activation of Toll-like receptors (TLRs) induces inflammatory gene expression to mediate tissue repair. However, DAMPs have also been implicated in diseases where excessive inflammation plays a key role in pathogenesis, including rheumatoid arthritis (RA), cancer, and atherosclerosis. TLR activation by DAMPs may initiate positive feedback loops where increasing tissue damage perpetuates pro-inflammatory responses leading to chronic inflammation. Here we explore the current knowledge about distinct signalling cascades resulting from self TLR activation. We also discuss the involvement of endogenous TLR activators in disease and highlight how specifically targeting DAMPs may yield therapies that do not globally suppress the immune system.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Piccinini</LastName>
            <ForeName>A M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, 65 Aspenlea Road, Hammersmith, London W6 8LH, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Midwood</LastName>
            <ForeName>K S</ForeName>
            <Initials>KS</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>G0700108</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <Acronym>ARC_</Acronym>
            <Agency>Arthritis Research UK</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2010</Year>
          <Month>07</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mediators Inflamm</MedlineTA>
        <NlmUniqueID>9209001</NlmUniqueID>
        <ISSNLinking>0962-9351</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051193" MajorTopicYN="N">Toll-Like Receptors</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2009</Year>
          <Month>11</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2010</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2010</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2010</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2010</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">20706656</ArticleId>
        <ArticleId IdType="pmc">PMC2913853</ArticleId>
        <ArticleId IdType="doi">10.1155/2010/672395</ArticleId>
        <ArticleId IdType="pii">672395</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Matzinger P. Tolerance, danger, and the extended family. Annual Review of Immunology. 1994;12:991–1045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8011301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beutler B. Neo-ligands for innate immune receptors and the etiology of sterile inflammatory disease. Immunological Reviews. 2007;220(1):113–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17979843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. Journal of Leukocyte Biology. 2007;81(1):1–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17032697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell. 2002;111(7):927–930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12507420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medzhitov R, Janeway CA., Jr. Decoding the patterns of self and nonself by the innate immune system. Science. 2002;296(5566):298–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11951031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kono H, Rock KL. How dying cells alert the immune system to danger. Nature Reviews Immunology. 2008;8(4):279–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2763408</ArticleId>
            <ArticleId IdType="pubmed">18340345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, infection and cancer. International Immunopharmacology. 2007;7(10):1271–1285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17673142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liew FY, Xu D, Brint EK, O’Neill LAJ. Negative regulation of Toll-like receptor-mediated immune responses. Nature Reviews Immunology. 2005;5(6):446–458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15928677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lotze MT, Zeh HJ, Rubartelli A, et al.  The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunological Reviews. 2007;220(1):60–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17979840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A. Cancer: inflaming metastasis. Nature. 2009;457(7225):36–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19122629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Midwood KS, Piccinini AM, Sacre S. Targeting Toll-like receptors in autoimmunity. Current Drug Targets. 2009;10(11):1139–1155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19715534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. Journal of Immunology. 2000;164(2):558–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10623794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. International Immunology. 2000;12(11):1539–1546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11058573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M, Carpio DF, Zheng Y, et al.  An essential role of the NF-κB/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. Journal of Immunology. 2001;166(12):7128–7135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11390458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asea A, Rehli M, Kabingu E, et al.  Novel signal transduction pathway utilized by extracellular HSP70: role of Toll-like receptor (TLR) 2 and TLR4. Journal of Biological Chemistry. 2002;277(17):15028–15034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11836257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. Journal of Biological Chemistry. 2002;277(17):15107–15112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11842086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vabulas RM, Braedel S, Hilf N, et al.  The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. Journal of Biological Chemistry. 2002;277(23):20847–20853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11912201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roelofs MF, Boelens WC, Joosten LAB, et al.  Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. Journal of Immunology. 2006;176(11):7021–7027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16709864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wheeler DS, Chase MA, Senft AP, Poynter SE, Wong HR, Page K. Extracellular Hsp72, an endogenous DAMP, is released by virally infected airway epithelial cells and activates neutrophils via Toll-like receptor (TLR)-4. Respiratory Research. 2009;10:p. 31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2679007</ArticleId>
            <ArticleId IdType="pubmed">19405961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JS, Svetkauskaite D, He Q, et al.  Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. Journal of Biological Chemistry. 2004;279(9):7370–7377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14660645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Molecular Medicine. 2008;14(7-8):476–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2323334</ArticleId>
            <ArticleId IdType="pubmed">18431461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JS, Gamboni-Robertson F, He Q, et al.  High mobility group box 1 protein interacts with multiple Toll-like receptors. American Journal of Physiology. 2006;290(3):C917–C924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16267105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaefer L, Babelova A, Kiss E, et al.  The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. Journal of Clinical Investigation. 2005;115(8):2223–2233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1174916</ArticleId>
            <ArticleId IdType="pubmed">16025156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Midwood K, Sacre S, Piccinini AM, et al.  Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nature Medicine. 2009;15(7):774–780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19561617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S, Takahashi H, Lin W-W, et al.  Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457(7225):102–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2746432</ArticleId>
            <ArticleId IdType="pubmed">19122641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Termeer C, Benedix F, Sleeman J, et al.  Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. Journal of Experimental Medicine. 2002;195(1):99–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2196009</ArticleId>
            <ArticleId IdType="pubmed">11781369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. Journal of Immunology. 2002;168(10):5233–5239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11994480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Funderburg N, Lederman MM, Feng Z, et al.  Human β-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(47):18631–18635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2141828</ArticleId>
            <ArticleId IdType="pubmed">18006661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karikó K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. Journal of Biological Chemistry. 2004;279(13):12542–12550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14729660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vollmer J, Tluk S, Schmitz C, et al.  Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. Journal of Experimental Medicine. 2005;202(11):1575–1585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213330</ArticleId>
            <ArticleId IdType="pubmed">16330816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416(6881):603–607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11948342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hurst J, Prinz N, Lorenz M, et al.  TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1β and caspase-1 in monocytes and dendritic cells. Immunobiology. 2009;214(8):683–691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19249118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Döring Y, Hurst J, Lorenz M, et al.  Human antiphospholipid antibodies induce TNFα in monocytes via Toll-like receptor 8. Immunobiology. 2010;215(3):230–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19457574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satta N, Dunoyer-Geindre S, Reber G, et al.  The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood. 2007;109(4):1507–1514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17082324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulla MJ, Brosens JJ, Chamley LW, et al.  Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. American Journal of Reproductive Immunology. 2009;62(2):96–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2772057</ArticleId>
            <ArticleId IdType="pubmed">19614626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierangeli SS, Vega-Ostertag ME, Raschi E, et al.  Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Annals of the Rheumatic Diseases. 2007;66(10):1327–1333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1994302</ArticleId>
            <ArticleId IdType="pubmed">17261530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erridge C, Samani NJ. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29(11):1944–1949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19661481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee K-M, Seong S-Y. Partial role of TLR4 as a receptor responding to damage-associated molecular pattern. Immunology Letters. 2009;125(1):31–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19501120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavassani KA, Ishii M, Wen H, et al.  TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. Journal of Experimental Medicine. 2008;205(11):2609–2621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2571935</ArticleId>
            <ArticleId IdType="pubmed">18838547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsan M-F, Gao B. Endogenous ligands of Toll-like receptors. Journal of Leukocyte Biology. 2004;76(3):514–519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15178705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsan M-F, Gao B. Heat shock proteins and immune system. Journal of Leukocyte Biology. 2009;85(6):905–910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19276179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radsak MP, Hilf N, Singh-Jasuja H, et al.  The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood. 2003;101(7):2810–2815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12446445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osterloh A, Kalinke U, Weiss S, Fleischer B, Breloer M. Synergistic and differential modulation of immune responses by Hsp60 and lipopolysaccharide. Journal of Biological Chemistry. 2007;282(7):4669–4680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17164250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warger T, Hilf N, Rechtsteiner G, et al.  Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. Journal of Biological Chemistry. 2006;281(32):22545–22553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16754684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Habich C, Kempe K, Van Der Zee R, et al.  Heat shock protein 60: specific binding of lipopolysaccharide. Journal of Immunology. 2005;174(3):1298–1305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15661886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian J, Avalos AM, Mao S-Y, et al.  Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nature Immunology. 2007;8(5):487–496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17417641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandholtz L, Guo Y, Palmberg C, et al.  Hsp90 binds CpG oligonucleotides directly: implications for Hsp90 as a missing link in CpG signaling and recognition. Cellular and Molecular Life Sciences. 2003;60(2):422–429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12678505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanai H, Ban T, Wang Z, et al.  HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 2009;462(7269):99–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19890330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medzhitov R. Toll-like receptors and innate immunity. Nature Reviews Immunology. 2001;1(2):135–145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11905821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L, Botos I, Wang Y, et al.  Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. Science. 2008;320(5874):379–381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2761030</ArticleId>
            <ArticleId IdType="pubmed">18420935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin MS, Kim SE, Heo JY, et al.  Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell. 2007;130(6):1071–1082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17889651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HM, Park BS, Kim J-I, et al.  Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007;130(5):906–917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17803912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park BS, Song DH, Kim HM, Choi B-S, Lee H, Lee J-O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 2009;458(7242):1191–1195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19252480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyake K. Roles for accessory molecules in microbial recognition by Toll-like receptors. Journal of Endotoxin Research. 2006;12(4):195–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16953972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossignol DP, Lynn M. TLR4 antagonists for endotoxemia and beyond. Current Opinion in Investigational Drugs. 2005;6(5):496–502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15912963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teghanemt A, Zhang D, Levis EN, Weiss JP, Gioannini TL. Molecular basis of reduced potency of underacylated endotoxins. Journal of Immunology. 2005;175(7):4669–4676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16177114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimazu R, Akashi S, Ogata H, et al.  MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. Journal of Experimental Medicine. 1999;189(11):1777–1782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2193086</ArticleId>
            <ArticleId IdType="pubmed">10359581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nature Medicine. 2009;15(4):410–416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2789255</ArticleId>
            <ArticleId IdType="pubmed">19330007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trompette A, Divanovic S, Visintin A, et al.  Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature. 2009;457(7229):585–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2843411</ArticleId>
            <ArticleId IdType="pubmed">19060881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn JH, Oh YJ, Kim ES, Choi JE, Shin J-S. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-α production in human monocytes. Journal of Immunology. 2008;180(7):5067–5074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18354232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagai Y, Kobayashi T, Motoi Y, et al.  The radioprotective 105/MD-1 complex links TLR2 and TLR4/MD-2 in antibody response to microbial membranes. Journal of Immunology. 2005;174(11):7043–7049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15905547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Divanovic S, Trompette A, Atabani SF, et al.  Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nature Immunology. 2005;6(6):571–578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2144914</ArticleId>
            <ArticleId IdType="pubmed">15852007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Latz E, Visintin A, Lien E, et al.  Lipopolysaccharide rapidly traffics to and from the golgi apparatus with the Toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. Journal of Biological Chemistry. 2002;277(49):47834–47843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12324469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Z, Georgel P, Du X, et al.  CD14 is required for MyD88-independent LPS signaling. Nature Immunology. 2005;6(6):565–570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15895089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakata T, Yasuda M, Fujita M, et al.  CD14 directly binds to triacylated lipopeptides and facilitates recognition of the lipopeptides by the receptor complex of Toll-like receptors 2 and 1 without binding to the complex. Cellular Microbiology. 2006;8(12):1899–1909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16848791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H-K, Dunzendorfer S, Soldau K, Tobias PS. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity. 2006;24(2):153–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16473828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoebe K, Georgel P, Rutschmann S, et al.  CD36 is a sensor of diacylglycerides. Nature. 2005;433(7025):523–527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15690042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park HS, Jung HY, Park EY, Kim J, Lee WJ, Bae YS. Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-κB. Journal of Immunology. 2004;173(6):3589–3593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15356101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park HS, Chun JN, Jung HY, Choi C, Bae YS. Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. Cardiovascular Research. 2006;72(3):447–455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17064675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. Journal of Experimental Medicine. 2003;197(9):1107–1117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2193968</ArticleId>
            <ArticleId IdType="pubmed">12719479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowdish DME, Sakamoto K, Kim M-J, et al.  MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and mycobacterium tuberculosis. PLoS Pathogens. 2009;5(6) Article ID e1000474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2688075</ArticleId>
            <ArticleId IdType="pubmed">19521507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horvath G, Young S, Latz E. Toll-like receptor interactions imaged by FRET microscopy and GFP fragment reconstitution. Methods in Molecular Biology. 2009;517:33–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19378018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami S, Iwaki D, Mitsuzawa H, et al.  Surfactant protein A inhibits peptidoglycan-induced tumor necrosis factor-α secretion in U937 cells and alveolar macrophages by direct interaction with Toll-like receptor 2. Journal of Biological Chemistry. 2002;277(9):6830–6837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11724772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato M, Sano H, Iwaki D, et al.  Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-κB activation and TNF-α secretion are down-regulated by lung collectin surfactant protein A. Journal of Immunology. 2003;171(1):417–425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12817025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodgkinson CP, Patel K, Ye S. Functional Toll-like receptor 4 mutations modulate the response to fibrinogen. Thrombosis and Haemostasis. 2008;100(2):301–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18690351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. Journal of Biological Chemistry. 2003;278(3):1561–1568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12424240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. Journal of Immunology. 2000;164(1):13–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10604986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. Journal of Immunology. 2002;168(12):5989–5992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12055204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohya M, Nishitani C, Sano H, et al.  Human pulmonary surfactant protein D binds the extracellular domains of Toll-like receptors 2 and 4 through the carbohydrate recognition domain by a mechanism different from its binding to phosphatidylinositol and lipopolysaccharide. Biochemistry. 2006;45(28):8657–8664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16834340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curran CS, Demick KP, Mansfield JM. Lactoferrin activates macrophages via TLR4-dependent and—independent signaling pathways. Cellular Immunology. 2006;242(1):23–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17034774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okamura Y, Watari M, Jerud ES, et al.  The extra domain a of fibronectin activates Toll-like receptor 4. Journal of Biological Chemistry. 2001;276(13):10229–10233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11150311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation. 2006;116(11):3015–3025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1616196</ArticleId>
            <ArticleId IdType="pubmed">17053832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Graaf R, Kloppenburg G, Kitslaar PJHM, Bruggeman CA, Stassen F. Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. Microbes and Infection. 2006;8(7):1859–1865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16843693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koh J-M, Lee Y-S, Kim YS, et al.  Heat shock protein 60 causes osteoclastic bone resorption via Toll-like receptor-2 in estrogen deficiency. Bone. 2009;45(4):650–660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19527807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen-Sfady M, Nussbaum G, Pevsner-Fischer M, et al.  Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. Journal of Immunology. 2005;175(6):3594–3602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16148103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gondokaryono SP, Ushio H, Niyonsaba F, et al.  The extra domain A of fibronectin stimulates murine mast cells via Toll-like receptor 4. Journal of Leukocyte Biology. 2007;82(3):657–665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17575266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babelova A, Moreth K, Tsalastra-Greul W, et al.  Biglycan, a danger signal that activates the NLRP3 inflammasome via Toll-like and P2X receptors. Journal of Biological Chemistry. 2009;284(36):24035–24048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2781998</ArticleId>
            <ArticleId IdType="pubmed">19605353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor KR, Yamasaki K, Radek KA, et al.  Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. Journal of Biological Chemistry. 2007;282(25):18265–18275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17400552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. Journal of Clinical Investigation. 2005;115(2):407–417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC544604</ArticleId>
            <ArticleId IdType="pubmed">15668740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urbonaviciute V, Fürnrohr BG, Meister S, et al.  Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. Journal of Experimental Medicine. 2008;205(13):3007–3018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2605236</ArticleId>
            <ArticleId IdType="pubmed">19064698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lande R, Gregorio J, Facchinetti V, et al.  Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564–569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17873860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganguly D, Chamilos G, Lande R, et al.  Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. Journal of Experimental Medicine. 2009;206(9):1983–1994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2737167</ArticleId>
            <ArticleId IdType="pubmed">19703986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lau CM, Broughton C, Tabor AS, et al.  RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. Journal of Experimental Medicine. 2005;202(9):1171–1177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213226</ArticleId>
            <ArticleId IdType="pubmed">16260486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity. 2003;19(6):837–847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14670301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gay NJ, Gangloff M. Structure and function of Toll receptors and their ligands. Annual Review of Biochemistry. 2007;76:141–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17362201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mollen K, Mollen K, Kaczorowski D, et al.  MD2 and CD14 mediate toll-like receptor 4 (TLR4) activation by high mobility group box 1 (HMGB1) Journal of the American College of Surgeons. 2007;205(3, supplement):p. S28.</Citation>
        </Reference>
        <Reference>
          <Citation>Jin MS, Lee J-O. Structures of the Toll-like receptor family and its ligand complexes. Immunity. 2008;29(2):182–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18701082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kenny EF, O’Neill LAJ. Signalling adaptors used by Toll-like receptors: an update. Cytokine. 2008;43(3):342–349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18706831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschfeld M, Weis JJ, Toshchakov V, et al.  Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infection and Immunity. 2001;69(3):1477–1482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC98044</ArticleId>
            <ArticleId IdType="pubmed">11179315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones BW, Heldwein KA, Means TK, Saukkonen JJ, Fenton MJ. Differential roles of Toll-like receptors in the elicitation of proinflammatory responses by macrophages. Annals of the Rheumatic Diseases. 2001;60(supplement 3):iii6–iii12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1766663</ArticleId>
            <ArticleId IdType="pubmed">11890657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agrawal S, Agrawal A, Doughty B, et al.  Cutting edge: different Toll-Like receptor agonists instruct ddendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. Journal of Immunology. 2003;171(10):4984–4989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14607893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barr TA, Brown S, Ryan G, Zhao J, Gray D. TLR-mediated stimulation of APC: distinct cytokine responses of B cells and dendritic cells. European Journal of Immunology. 2007;37(11):3040–3053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2699383</ArticleId>
            <ArticleId IdType="pubmed">17918201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lundberg AM, Drexler SK, Monaco C, et al.  Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood. 2007;110(9):3245–3252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17660379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JS, Arcaroli J, Yum H-K, et al.  Activation of gene expression in human neutrophils by high mobility group box 1 protein. American Journal of Physiology. 2003;284(4):C870–C879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12620891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silva E, Arcaroli J, He Q, et al.  HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury. Intensive Care Medicine. 2007;33(10):1829–1839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17581740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dvorak HF, Senger DR, Dvorak AM. Regulation of extravascular coagulation by microvascular permeability. Science. 1985;227(4690):1059–1061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3975602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCachren SS, Lightner VA. Expression of human tenascin in synovitis and its regulation by interleukin-1. Arthritis and Rheumatism. 1992;35(10):1185–1196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1384510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salter DM. Tenascin is increased in cartilage and synovium from arthritic knees. British Journal of Rheumatology. 1993;32(9):780–786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7690296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schett G, Redlich K, Xu Q, et al.  Enhanced expression of heat shock protein 70 (hsp70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue: differential regulation of hsp70 expression and hsf1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and antiinflammatory drugs. Journal of Clinical Investigation. 1998;102(2):302–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC508888</ArticleId>
            <ArticleId IdType="pubmed">9664071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott DL, Delamere JP, Walton KW. The distribution of fibronectin in the pannus in rheumatoid arthritis. British Journal of Experimental Pathology. 1981;62(4):362–368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2041679</ArticleId>
            <ArticleId IdType="pubmed">7028072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniguchi N, Kawahara K-I, Yone K, et al.  High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis and Rheumatism. 2003;48(4):971–981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12687539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu D, Rumore PM, Liu Q, Steinman CR. Soluble oligonucleosomal complexes in synovial fluid from inflamed joints. Arthritis and Rheumatism. 1997;40(4):648–654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9125246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schenk S, Muser J, Vollmer G, Chiquet-Ehrismann R. Tenascin-C in serum: a questionable tumor marker. International Journal of Cancer. 1995;61(4):443–449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7538974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Bloom O, Zhang M, et al.  HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248–251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10398600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urbonaviciute V, Fürnrohr BG, Weber C, et al.  Factors masking HMGB1 in human serum and plasma. Journal of Leukocyte Biology. 2007;81(1):67–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17060363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallgren R, Eklund A, Engstrom-Laurent A, Schmekel B. Hyaluronate in bronchoalveolar lavage fluid: a new marker in sarcoidosis reflecting pulmonary disease. British Medical Journal. 1985;290(6484):1778–1781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1415927</ArticleId>
            <ArticleId IdType="pubmed">3924250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milman N, Kristensen MS, Bentsen K. Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid from patients with pulmonary fibrosis. APMIS. 1995;103(10):749–754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8534435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riise GC, Ahlstedt S, Larsson S, et al.  Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid. Thorax. 1995;50(4):360–365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC474276</ArticleId>
            <ArticleId IdType="pubmed">7785007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersson Å, Covacu R, Sunnemark D, et al.  Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. Journal of Leukocyte Biology. 2008;84(5):1248–1255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18644848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. Journal of Leukocyte Biology. 2007;81(1):28–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16943388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson GB, Brunn GJ, Platt JL. Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-Like receptor 4. Journal of Immunology. 2004;172(1):20–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14688304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher JJ. DAMPs ramp up drug toxicity. Journal of Clinical Investigation. 2009;119(2):246–249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2631305</ArticleId>
            <ArticleId IdType="pubmed">19244605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishii KJ, Suzuki K, Coban C, et al.  Genomic DNA released by dying cells induces the maturation of APCs. Journal of Immunology. 2001;167(5):2602–2607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11509601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang S-A, Kruzel ML, Actor JK. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. International Immunopharmacology. 2005;5(3):591–599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15683854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. Journal of Immunology. 2006;177(2):1272–1281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16818787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tani K, Murphy WJ, Chertov O, et al.  Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. International Immunology. 2000;12(5):691–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10784615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rovere-Querini P, Capobianco A, Scaffidi P, et al.  HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Reports. 2004;5(8):825–830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1299116</ArticleId>
            <ArticleId IdType="pubmed">15272298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawakami A, Osaka M, Aikawa M, et al.  Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circulation Research. 2008;103(12):1402–1409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2994199</ArticleId>
            <ArticleId IdType="pubmed">18974386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agnello D, Wang H, Yang H, Tracey KJ, Ghezzi P. HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine. 2002;18(4):231–236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12126646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu K, Mori S, Takahashi HK, et al.  Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB Journal. 2007;21(14):3904–3916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17628015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Connor KA, Hansen MK, Pugh CR, et al.  Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects. Cytokine. 2003;24(6):254–265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14609567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology. 2002;123(3):790–802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12198705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pullerits R, Jonsson I-M, Verdrengh M, et al.  High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis and Rheumatism. 2003;48(6):1693–1700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12794838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imaeda AB, Watanabe A, Sohail MA, et al.  Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. Journal of Clinical Investigation. 2009;119(2):305–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2631294</ArticleId>
            <ArticleId IdType="pubmed">19164858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsung A, Sahai R, Tanaka H, et al.  The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. Journal of Experimental Medicine. 2005;201(7):1135–1143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213120</ArticleId>
            <ArticleId IdType="pubmed">15795240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. Cutting edge: HMG-1 as a mediator of acute lung inflammation. Journal of Immunology. 2000;165(6):2950–2954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10975801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X, Yang H, Sakuragi T, et al.  
α-chemokine receptor blockade reduces high mobility group box 1 protein-induced lung inflammation and injury and improves survival in sepsis. American Journal of Physiology. 2005;289(4):L583–L590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15937067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueno H, Matsuda T, Hashimoto S, et al.  Contributions of high mobility group box protein in experimental and clinical acute lung injury. American Journal of Respiratory and Critical Care Medicine. 2004;170(12):1310–1316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15374839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan MH, Sun Z, Opitz SL, Schmidt TE, Peters JH, George EL. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood. 2004;104(1):11–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14976060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Zoelen MAD, Vogl T, Foell D, et al.  Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. American Journal of Respiratory and Critical Care Medicine. 2009;180(11):1098–1106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19762566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Croce K, Gao H, Wang Y, et al.  Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation. 2009;120(5):427–436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3070397</ArticleId>
            <ArticleId IdType="pubmed">19620505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ziegler G, Prinz V, Albrecht MW, et al.  Mrp-8 and -14 mediate CNS injury in focal cerebral ischemia. Biochimica et Biophysica Acta. 2009;1792(12):1198–1204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19835955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogl T, Tenbrock K, Ludwig S, et al.  Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nature Medicine. 2007;13(9):1042–1049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17767165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talts JF, Wirl G, Dictor M, Muller WJ, Fässler R. Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. Journal of Cell Science. 1999;112(12):1855–1864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10341205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang D, Liang J, Fan J, et al.  Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nature Medicine. 2005;11(11):1173–1179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16244651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y-Y, Lee C-H, Dedaj R, et al.  High-molecular-weight hyaluronan—a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats. Critical Care. 2008;12(4, article R102)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2575591</ArticleId>
            <ArticleId IdType="pubmed">18691420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davé SH, Tilstra JS, Matsuoka K, et al.  Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. Journal of Leukocyte Biology. 2009;86(3):633–643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2735284</ArticleId>
            <ArticleId IdType="pubmed">19454652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maeda S, Hikiba Y, Shibata W, et al.  Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochemical and Biophysical Research Communications. 2007;360(2):394–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17599806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa EN, Ishizaka A, Tasaka S, et al.  Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. American Journal of Respiratory and Critical Care Medicine. 2006;174(4):400–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16728713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawa H, Ueda T, Takeyama Y, et al.  Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis. World Journal of Gastroenterology. 2006;12(47):7666–7670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4088050</ArticleId>
            <ArticleId IdType="pubmed">17171797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang R, Harada T, Mollen KP, et al.  Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Molecular Medicine. 2006;12(4–6):105–114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1578769</ArticleId>
            <ArticleId IdType="pubmed">16953558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JY, Park JS, Strassheim D, et al.  HMGB1 contributes to the development of acute lung injury after hemorrhage. American Journal of Physiology. 2005;288(5):L958–L965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15640285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suda K, Kitagawa Y, Ozawa S, et al.  Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World Journal of Surgery. 2006;30(9):1755–1762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16850155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Ochani M, Li J, et al.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(1):296–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC314179</ArticleId>
            <ArticleId IdType="pubmed">14695889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin S, Wang H, Yuan R, et al.  Role of HMGB1 in apoptosis-mediated sepsis lethality. Journal of Experimental Medicine. 2006;203(7):1637–1642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2118346</ArticleId>
            <ArticleId IdType="pubmed">16818669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G, Li J, Qiang X, et al.  Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. Journal of Lipid Research. 2005;46(4):623–627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15687351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulloa L, Batliwalla FM, Andersson U, Gregersen PK, Tracey KJ. High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis and Rheumatism. 2003;48(4):876–881.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12687528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Liao H, Ochani M, et al.  Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nature Medicine. 2004;10(11):1216–1221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15502843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chorny A, Delgado M. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. American Journal of Pathology. 2008;172(5):1297–1302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2329838</ArticleId>
            <ArticleId IdType="pubmed">18385521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan P, Cardinal J, Dhupar R, et al.  Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality. Journal of Leukocyte Biology. 2009;86(3):625–632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19487305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersson U, Erlandsson-Harris H. HMGB1 is a potent trigger of arthritis. Journal of Internal Medicine. 2004;255(3):344–350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14871458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rice JW, Veal JM, Fadden RP, et al.  Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis and Rheumatism. 2008;58(12):3765–3775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19035474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman RI, Mintzer B, Zhu D, et al.  Potent triazolothione inhibitor of heat-shock protein-90. Chemical Biology and Drug Design. 2009;74(1):43–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19519743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagiwara S, Iwasaka H, Togo K, Noguchi T. A neutrophil elastase inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1. Inflammation. 2008;31(4):227–234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18536984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harada N, Okajima K, Isobe H. Role of neutrophil elastase in development of pulmonary vascular injury and septic shock in rats. Shock. 2008;30(4):379–387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18323746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morohoshi Y, Matsuoka K, Chinen H, et al.  Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. Journal of Gastroenterology. 2006;41(4):318–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16741610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakimoto K, Matsukawa A, Yoshinaga M, Nakamura H. Suppressive effect of a neutrophil elastase inhibitor on the development of collagen-induced arthritis. Cellular Immunology. 1995;165(1):26–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7671322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchida Y, Freitas MCS, Zhao D, Busuttil RW, Kupiec-Weglinski JW. The inhibition of neutrophil elastase ameliorates mouse liver damage due to ischemia and reperfusion. Liver Transplantation. 2009;15(8):939–947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2752954</ArticleId>
            <ArticleId IdType="pubmed">19642132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiratsuka S, Watanabe A, Sakurai Y, et al.  The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nature Cell Biology. 2008;10(11):1349–1355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18820689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Reviews Immunology. 2005;5(4):331–342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15803152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantell LL, Parrish WR, Ulloa L. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock. 2006;25(1):4–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16369179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parrish WR, Gallowitsch-Puerta M, Czura CJ, Tracey KJ. Experimental therapeutic strategies for severe sepsis: mediators and mechanisms. Annals of the New York Academy of Sciences. 2008;1144:210–236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19076379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voll RE, Urbonaviciute V, Fürnrohr B, Herrmann M, Kalden JR. The role of high-mobility group box 1 protein in the pathogenesis of autoimmune diseases. Current Rheumatology Reports. 2008;10(5):341–342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18817635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. Journal of Internal Medicine. 2004;255(3):320–331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14871456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Research and Therapy. 2008;10(3):p. 209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2483460</ArticleId>
            <ArticleId IdType="pubmed">18598385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Musumeci D, Roviello GN, Moccia M, et al.  Bent oligonucleotide duplexes as HMGB1 inhibitors: a comparative study. Nucleosides, Nucleotides and Nucleic Acids. 2007;26(10–12):1447–1450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18066803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan Z, Chen J, Zhang Y, Peng Y. Construction and characterization of the HMGB1 mutant as a competitive antagonist to HMGB1 induced cytokines release. Biochemical and Biophysical Research Communications. 2008;372(4):703–707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18515078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abeyama K, Stern DM, Ito Y, et al.  The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. Journal of Clinical Investigation. 2005;115(5):1267–1274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1077171</ArticleId>
            <ArticleId IdType="pubmed">15841214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12110890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gardella S, Andrei C, Ferrera D, et al.  The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Reports. 2002;3(10):995–1001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1307617</ArticleId>
            <ArticleId IdType="pubmed">12231511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foell D, Wittkowski H, Roth J. Mechanisms of disease: a ’DAMP’ view of inflammatory arthritis. Nature Clinical Practice Rheumatology. 2007;3(7):382–390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17599072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunn GJ, Bungum MK, Johnson GB, Platt JL. Conditional signaling by Toll-like receptor 4. FASEB Journal. 2005;19(7):872–874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15738005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kliment CR, Tobolewski JM, Manni ML, Tan RJ, Enghild J, Oury TD. Extracellular superoxide dismutase protects against matrix degradation of heparan sulfate in the lung. Antioxidants and Redox Signaling. 2008;10(2):261–268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2289772</ArticleId>
            <ArticleId IdType="pubmed">17961072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goto M, Hanyu T, Yoshio T, et al.  Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. Clinical and Experimental Rheumatology. 2001;19(4):377–383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11491492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Eden W, Van Der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nature Reviews Immunology. 2005;5(4):318–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15803151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayakawa M, Katabami K, Wada T, et al.  Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients. Shock. 2010;33(1):14–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19487982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Togo S, Matsuo K, Ishibe A, et al.  Usefulness of a selective neutrophil elastase inhibitor (sivelestat) in septic ARDS patients after gastrointestinal surgery. Hepato-Gastroenterology. 2008;55(84):967–973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18705309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izuishi K, Tsung A, Jeyabalan G, et al.  Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. Journal of Immunology. 2006;176(12):7154–7158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16751357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klune JR, Billiar TR, Tsung A. HMGB1 preconditioning: therapeutic application for a danger signal? Journal of Leukocyte Biology. 2008;83(3):558–563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17938274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. British Journal of Experimental Pathology. 1989;70(6):697–704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2040730</ArticleId>
            <ArticleId IdType="pubmed">2690922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gariboldi S, Palazzo M, Zanobbio L, et al.  Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of β-defensin 2 via TLR2 and TLR4. Journal of Immunology. 2008;181(3):2103–2110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18641349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chesler EJ, Miller DR, Branstetter LR, et al.  The Collaborative Cross at Oak Ridge National Laboratory: developing a powerful resource for systems genetics. Mammalian Genome. 2008;19(6):382–389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2745091</ArticleId>
            <ArticleId IdType="pubmed">18716833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Neill LAJ. When signaling pathways collide: positive and negative regulation of Toll-like receptor signal transduction. Immunity. 2008;29(1):12–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18631453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stack J, Haga IR, Schröder M, et al.  Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. Journal of Experimental Medicine. 2005;201(6):1007–1018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213104</ArticleId>
            <ArticleId IdType="pubmed">15767367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li K, Foy E, Ferreon JC, et al.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(8):2992–2997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC548795</ArticleId>
            <ArticleId IdType="pubmed">15710891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu G, Friggeri A, Yang Y, Park Y-J, Tsuruta Y, Abraham E. miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(37):15819–15824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2747202</ArticleId>
            <ArticleId IdType="pubmed">19721002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Chen G-Y, Zheng P. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends in Immunology. 2009;30(12):557–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2788100</ArticleId>
            <ArticleId IdType="pubmed">19786366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G-Y, Tang J, Zheng P, Liu Y. CD24 and siglec-10 selectively repress tissue damage—induced immune responses. Science. 2009;323(5922):1722–1725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2765686</ArticleId>
            <ArticleId IdType="pubmed">19264983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raby AC, Le Bouder E, Colmont C, et al.  Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. Journal of Immunology. 2009;183(1):506–517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19542461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. Journal of Immunology. 2001;167(5):2887–2894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11509636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood. 2009;113(2):429–437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2615655</ArticleId>
            <ArticleId IdType="pubmed">18952897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A. Is serum amyloid A an endogenous TLR4 agonist? Journal of Leukocyte Biology. 2008;83(5):1174–1180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18252871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng N, He R, Tian J, Ye PP, Ye RD. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. Journal of Immunology. 2008;181(1):22–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2464454</ArticleId>
            <ArticleId IdType="pubmed">18566366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biragyn A, Ruffini PA, Leifer CA, et al.  Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science. 2002;298(5595):1025–1029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12411706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devaney JM, Greene CM, Taggart CC, Carroll TP, O’Neill SJ, McElvaney NG. Neutrophil elastase up-regulates interleukin-8 via Toll-like receptor 4. FEBS Letters. 2003;544(1–3):129–132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12782302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu XH, Shah PK, Faure E, et al.  Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104(25):3103–3108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11748108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bae YS, Lee JH, Choi SH, et al.  Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: Toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circulation Research. 2009;104(2):210–218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2720065</ArticleId>
            <ArticleId IdType="pubmed">19096031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaeffler A, Gross P, Buettner R, et al.  Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-κB pathway in adipocytes links nutritional signalling with innate immunity. Immunology. 2009;126(2):233–245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2632685</ArticleId>
            <ArticleId IdType="pubmed">18624726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang D, Chen Q, Shao BS, et al.  Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. Journal of Experimental Medicine. 2008;205(1):79–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2234357</ArticleId>
            <ArticleId IdType="pubmed">18195069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Little PJ, Osman N, O’Brien KD. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Current Opinion in Lipidology. 2008;19(5):448–454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18769225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams KJ. Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis. Current Opinion in Lipidology. 2001;12(5):477–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11561166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaefer L, Raslik I, Grone HJ, et al.  Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. FASEB Journal. 2001;15(3):559–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11259366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cs-Szabo G, Roughley PJ, Plaas AHK, Glant TT. Large and small proteoglycans of osteoarthritic and rheumatoid articular cartilage. Arthritis and Rheumatism. 1995;38(5):660–668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7538297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polgár A, Falus A, Koó É, et al.  Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases. Rheumatology. 2003;42(4):522–527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12649398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galamb O, Sipos F, Spisák S, et al.  Potential biomarkers of colorectal adenoma-dysplasia-carcinoma progression: mRNA expression profiling and in situ protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes. Cellular Oncology. 2009;31(1):19–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4618585</ArticleId>
            <ArticleId IdType="pubmed">19096147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishino R, Honda M, Yamashita T, et al.  Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. Journal of Hepatology. 2008;49(2):207–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18490072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mintz MB, Sowers R, Brown KM, et al.  An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Research. 2005;65(5):1748–1754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15753370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber CK, Sommer G, Michl P, et al.  Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology. 2001;121(3):657–667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11522750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danesh J, Lewington S, Thompson SG, et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Journal of the American Medical Association. 2005;294(14):1799–1809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16219884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Minno G, Mancini M. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis. 1990;10(1):1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2404490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams RA, Schachtrup C, Davalos D, Tsigelny I, Akassoglou K. Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: lessons from multiple sclerosis. Current Medicinal Chemistry. 2007;14(27):2925–2936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18045138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rybarczyk BJ, Simpson-Haidaris PJ. Fibrinogen assembly, secretion, and deposition into extracellular matrix by MCF-7 human breast carcinoma cells. Cancer Research. 2000;60(7):2033–2039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10766195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bidwell J, McCabe R, Rougraff B, et al.  Tissue matrix protein expression in human osteoblasts, osteosarcoma tumors, and osteosarcoma cell lines. Molecular Biology Reports. 1997;24(4):271–282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9403869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Keulen JK, de Kleijn DP, Nijhuis MMO, et al.  Levels of extra domain A containing fibronectin in human atherosclerotic plaques are associated with a stable plaque phenotype. Atherosclerosis. 2007;195(1):e83–e91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17416372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Széll M, Bata-Csörgo Z, Koreck A, et al.  Proliferating keratinocytes are putative sources of the psoriasis susceptibility-related EDA+ (extra domain A of fibronectin) oncofetal fibronectin. Journal of Investigative Dermatology. 2004;123(3):537–546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15304094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ting KM, Rothaupt D, McCormick TS, et al.  Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of psoriatic uninvolved skin. Journal of Investigative Dermatology. 2000;114(4):706–711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10733677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satoi S, Kitade H, Hiramatsu Y, et al.  Increased extra domain-A containing fibronectin and hepatic dysfunction during septic response: an in vivo and in vitro study. Shock. 2000;13(6):492–496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10847638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rybak J-N, Roesli C, Kaspar M, Villa A, Neri D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Research. 2007;67(22):10948–10957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18006840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villa A, Trachsel E, Kaspar M, et al.  A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. International Journal of Cancer. 2008;122(11):2405–2413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18271006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruse R, Merten M, Yoshida K, Schmidt A, Völker W, Buddecke E. Cholesterol-dependent changes of glycosaminoglycan pattern in human aorta. Basic Research in Cardiology. 1996;91(5):344–352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8922251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I, Ilan N. Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Modern Pathology. 2007;20(1):8–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17041566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aotsuka S, Okawa-Takatsuji M, Kinoshita M, Yokohari R. Analysis of negatively charged dye-binding antibodies reactive with double-stranded DNA and heparan sulfate in serum from patients with rheumatic diseases. Clinical and Experimental Immunology. 1988;73(3):436–442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1541765</ArticleId>
            <ArticleId IdType="pubmed">2974766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen E, Doweck I, Naroditsky I, et al.  Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer. 2008;113(5):1004–1011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2625296</ArticleId>
            <ArticleId IdType="pubmed">18618498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKenzie EA. Heparanase: a target for drug discovery in cancer and inflammation. British Journal of Pharmacology. 2007;151(1):1–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2012981</ArticleId>
            <ArticleId IdType="pubmed">17339837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porto A, Palumbo R, Pieroni M, et al.  Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB Journal. 2006;20(14):2565–2566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17060403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devaraj S, Dasu MR, Park SH, Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia. 2009;52(8):1665–1668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2709882</ArticleId>
            <ArticleId IdType="pubmed">19455302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popovic K, Ek M, Espinosa A, et al.  Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis and Rheumatism. 2005;52(11):3639–3645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16255056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ek M, Popovic K, Harris HE, Nauclér CS, Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren’s syndrome. Arthritis and Rheumatism. 2006;54(7):2289–2294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16802368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshizaki A, Komura K, Iwata Y, et al.  Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. Journal of Clinical Immunology. 2009;29(2):180–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18825489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riganò R, Profumo E, Buttari B, et al.  Heat shock proteins and autoimmunity in patients with carotid atherosclerosis. Annals of the New York Academy of Sciences. 2007;1107:1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17804527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Eden W, Wick G, Albani S, Cohen I. Stress, heat shock proteins, and autoimmunity: how immune responses to heat shock proteins are to be used for the control of chronic inflammatory diseases. Annals of the New York Academy of Sciences. 2007;1113:217–237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17584980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peetermans WE, D’Haens GR, Ceuppens JL, Rutgeerts P, Geboes K. Mucosal expression by B7-positive cells of the 60-kilodalton heat-shock protein in inflammatory bowel disease. Gastroenterology. 1995;108(1):75–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7528700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu S, et al.  The expression of molecular chaperone HSP90 and IL-6 in patients with systemic lupus erythematosus. Journal of Huazhong University of Science and Technology. Medical Sciences. 2006;26(6):664–666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17357483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cid C, García-Villanueva M, Salinas M, Alcázar A. Detection of anti-heat shock protein 90 β (Hsp90β) antibodies in cerebrospinal fluid. Journal of Immunological Methods. 2007;318(1-2):153–157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17112536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cid C, Regidor I, Poveda PD, Alcazar A. Expression of heat shock protein 90 at the cell surface in human neuroblastoma cells. Cell Stress &amp;amp; Chaperones. 2009;14(3):321–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2728257</ArticleId>
            <ArticleId IdType="pubmed">18800240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matysiak M, Makosa B, Walczak A, Selmaj K. Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex. Multiple Sclerosis. 2008;14(7):919–926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18573821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seung NR, Park EJ, Kim CW, et al.  Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4, and T-cell receptor γ
δ in plaque and guttate psoriasis. Journal of Cutaneous Pathology. 2007;34(12):903–911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18001412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kee C, Cheong KY, Pham K, Waterer GW, Temple SEL. Genetic variation in heat shock protein 70 is associated with septic shock: narrowing the association to a specific haplotype. International Journal of Immunogenetics. 2008;35(6):465–473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19046306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Messaoudi S, Peyrat JF, Brion JD, Alami M. Recent advances in Hsp90 inhibitors as antitumor agents. Anti-Cancer Agents in Medicinal Chemistry. 2008;8(7):761–782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18855578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo W, Rodina A, Chiosis G. Heat shock protein 90: translation from cancer to Alzheimer’s disease treatment? BMC Neuroscience. 2008;9(supplement 3, article S7)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2604891</ArticleId>
            <ArticleId IdType="pubmed">19090995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witter J, Roughley PJ, Webber C. The immunologic detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis. Arthritis and Rheumatism. 1987;30(5):519–529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2439090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshizaki A, Iwata Y, Komura K, et al.  Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. Journal of Rheumatology. 2008;35(9):1825–1829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18688912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. Journal of Biological Chemistry. 2006;281(9):5861–5868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16407205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henriksen PA, Sallenave J-M. Human neutrophil elastase: mediator and therapeutic target in atherosclerosis. International Journal of Biochemistry and Cell Biology. 2008;40(6-7):1095–1100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18289916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piwowar A, Knapik-Kordecka M, Warwas M. Concentration of leukocyte elastase in plasma and polymorphonuclear neutrophil extracts in type 2 diabetes. Clinical Chemistry and Laboratory Medicine. 2000;38(12):1257–1261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11205690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischbach W, Becker W, Mossner J. Leucocyte elastase in chronic inflammatory bowel diseases: a marker of inflammatory activity? Digestion. 1987;37(2):88–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3650181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bugren P, Rasmussen N, Isaksson B, Wieslander J. Anti-neutrophil cytoplasm antibodies, anti-GBM antibodies and anti-dsDNA antibodies in glomerulonephritis. European Journal of Clinical Investigation. 1992;22(12):783–792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1478249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Figueredo CM, Areas A, Sztajnbok FR, et al.  Higher elastase activity associated with lower IL-18 in GCF from juvenile systemic lupus patients. Oral Health &amp;amp; Preventive Dentistry. 2008;6(1):75–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18399311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong SN, Shah V, Dillon MJ. Anti-neutrophil cytoplasmic antibodies in childhood systemic lupus erythematosus. European Journal of Pediatrics. 1995;154(1):43–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7534707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsujimoto H, Ono S, Majima T, et al.  Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis. Shock. 2005;23(1):39–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15614130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JGM, Jochum M. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. Cancer Research. 2003;63(2):337–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12543785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada S, Yamaguchi K, Takahashi M, Ogawa M. Pancreatic elastase IIIA and its variants are expressed in pancreatic carcinoma cells. International Journal of Molecular Medicine. 2002;10(5):599–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12373299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniguchi K, Yang P, Jett J, et al.  Polymorphisms in the promoter region of the neutrophil elastase gene are associated with lung cancer development. Clinical Cancer Research. 2002;8(4):1115–1120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11948122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCormick MM, Rahimi F, Bobryshev YV, et al.  S100A8 and S100A9 in human arterial wall: implications for atherogenesis. Journal of Biological Chemistry. 2005;280(50):41521–41529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16216873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lugering N, Stoll R, Kucharzik T, et al.  Immunohistochemical distribution and serum levels of the Ca2+-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn’s disease. Digestion. 1995;56(5):406–414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8549885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lugering N, Stoll R, Schmid KW, et al.  The myeloic related protein MRP8/14 (27E10 antigen)—usefulness as a potential marker for disease activity in ulcerative colitis and putative biological function. European Journal of Clinical Investigation. 1995;25(9):659–664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7498239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haga H-J, Brun JG, Berntzen HB, Cervera R, Khamashta M, Hughes GRV. Calprotection in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus. 1993;2(1):47–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8485559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zenz R, Eferl R, Kenner L, et al.  Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005;437(7057):369–375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16163348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis and Rheumatism. 2004;50(12):3762–3771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15593206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odink K, Cerletti N, Bruggen J, et al.  Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature. 1987;330(6143):80–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3313057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youssef P, Roth J, Frosch M, et al.  Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. Journal of Rheumatology. 1999;26(12):2523–2528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10606357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallner K, Li C, Shah PK, et al.  Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation. 1999;99(10):1284–1289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10077510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amin K, Lúdvíksdóttir D, Janson C, et al.  Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. American Journal of Respiratory and Critical Care Medicine. 2000;162(6):2295–2301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11112154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karjalainen E-M, Lindqvist A, Laitinen LA, et al.  Airway inflammation and basement membrane tenascin in newly diagnosed atopic and nonatopic asthma. Respiratory Medicine. 2003;97(9):1045–1051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14509559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ljubimov AV, Burgeson RE, Butkowski RJ, et al.  Basement membrane abnormalities in human eyes with diabetic retinopathy. Journal of Histochemistry and Cytochemistry. 1996;44(12):1469–1479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8985139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loots MAM, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. Journal of Investigative Dermatology. 1998;111(5):850–857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9804349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riedl S, Tandara A, Reinshagen M, et al.  Serum tenascin-C is an indicator of inflammatory bowel disease activity. International Journal of Colorectal Disease. 2001;16(5):285–291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11686525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaarteenaho-Wiik R, Lakari E, Soini Y, Pollanen R, Kinnula VL, Paakko P. Tenascin expression and distribution in pleural inflammatory and fibrotic diseases. Journal of Histochemistry and Cytochemistry. 2000;48(9):1257–1268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10950882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paallysaho T, Tervo K, Kivela T, Virtanen I, Tarkkanen A, Tervo T. Cellular fibronectin and tenascin in an orbital nylon prosthesis removed because of infection caused by Staphylococcus aureus. Graefe’s Archive for Clinical and Experimental Ophthalmology. 1993;231(2):61–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7680328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutowski NJ, Newcombe J, Cuzner ML. Tenascin-R and C in multiple sclerosis lesions: relevance to extracellular matrix remodelling. Neuropathology and Applied Neurobiology. 1999;25(3):207–214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10417662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chevalier X, Groult N, Larget-Piet B, Zardi L, Hornebeck W. Tenascin distribution in articular cartilage from normal subjects and from patients with osteoarthritis and rheumatoid arthritis. Arthritis and Rheumatism. 1994;37(7):1013–1022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7517675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasegawa M, Nakoshi Y, Muraki M, et al.  Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. Journal of Orthopaedic Research. 2007;25(5):563–568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17262825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Letters. 2006;244(2):143–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16632194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sobel RA, Ahmed AS. White matter extracellular matrix chondroitin sulfate/dermatan sulfate proteoglycans in multiple sclerosis. Journal of Neuropathology and Experimental Neurology. 2001;60(12):1198–1207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11764092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer and Metastasis Reviews. 2009;28(1-2):233–245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19160015</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
